SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Michael Greene who wrote (863)5/28/1998 1:16:00 AM
From: M. Ramle  Read Replies (1) | Respond to of 10280
 
Michael:

Thanks for all this very enthusiastic info. It gives a good summary about the vast potential of SEPR within the next few years. The only question that comes to my mind is: Did SEPR management give any idea about when they expect the FDA to approve Levalbuterol ??? Thanks again and good luck to all.



To: Michael Greene who wrote (863)5/28/1998 6:33:00 AM
From: Frank Haims  Respond to of 10280
 
Thanks Michael. I could not attend the meeting and was delighted to hear your summary. I think the Nori deal with J& J will move into high gear because of the black box on Hismanel.
Sepracors split on that deal is the best they have done should be interesting. Frank


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News